{
    "clinical_study": {
        "@rank": "112524", 
        "arm_group": [
            {
                "arm_group_label": "Sequential Gefitinib With Pemetrexed/Platinum", 
                "arm_group_type": "Experimental", 
                "description": "Pemetrexed\tIV 500 mg/m2 \uff0cDAY2 DDP\tIV 75mg/m2 \uff0cDAY1 OR CAP\tIV AUC 5,DAY1 Gefitinib\tPO.\t250mg\tDAY3-16"
            }, 
            {
                "arm_group_label": "Pemetrexed/Platinum", 
                "arm_group_type": "Active Comparator", 
                "description": "Pemetrexed\tIV 500 mg/m2 \uff0cDAY2 DDP\tIV 75mg/m2 \uff0cDAY1 OR CAP\tIV AUC 5,DAY1"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to explore the Clinical Value of Sequential Gefitinib With\n      Pemetrexed/Platinum compare with Pemetrexed/Platinum for Advanced NSCLC."
        }, 
        "brief_title": "Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC", 
        "condition": "NSCLC", 
        "detailed_description": {
            "textblock": "Patients will be randomized to 2 groups"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18~70 years\n\n          2. Patients who were diagnosed by the histologic, cytologic diagnosis of IIIb-IV\n             non-small cell lung cancer\n\n          3. Presence of at least one index lesion measurable by CT scan or MRI\n\n          4. Ecog0-1\n\n          5. Expected life time longer than 12 weeks\n\n          6. Normal laboratory values:\n\n               -  leucocyte \u2265 4\u00d7109/L\n\n               -  neutrophil \u2265 1.5\u00d7109/L\n\n               -  platelet \u2265 100\u00d7109/L\n\n               -  Hemoglobin \u2265 10g/L\n\n               -  ALT and\n\n               -  AST \u2264 2.5\u00d7ULN (\u2264 5\u00d7ULN if liver metastasis)\n\n          7. Signed written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients have used drugs according to protocol\n\n          -  Patients were allergic to pemetrexed or cisplatin\n\n          -  Patients received radiotherapy or other biological treatment 4 weeks before the trial\n\n          -  Uncontrolled hydrothorax or hydropericardium\n\n          -  neuropathy toxicity \u2265 CTC 3\n\n          -  Severe symptomatic heart disease\n\n          -  Active upper gastrointestinal ulcer or digestive disfunction\n\n          -  Severe infection or metabolic disfunction\n\n          -  Patients with other malignant tumor\n\n          -  Uncontrolled brain metastases\n\n          -  Patients have accepted other clinical trials\n\n          -  Female patients during their pregnant and lactation period, or patients without\n             contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769066", 
            "org_study_id": "Gefitinib-2009-cjh"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sequential Gefitinib With Pemetrexed/Platinum", 
                "intervention_name": "Sequential Gefitinib With Pemetrexed/Platinum", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pemetrexed/Platinum", 
                "intervention_name": "Pemetrexed/Platinum", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Gefitinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Cancer hospital Fudan University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Random Open Exploratory Clinical Research of Sequential Gefitinib With Pemetrexed/Platinum Compare With Pemetrexed/Platinum Treatment for Advanced Non-small Cell Lung Cancer Exploratory Clinical Research", 
        "overall_official": {
            "affiliation": "Cancer hospital Fudan University", 
            "last_name": "Chang jian hua, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "12 weeks of non-progression rate", 
            "safety_issue": "No", 
            "time_frame": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769066"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Chang Jian Hua", 
            "investigator_title": "Deputy director of department of medical oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "PFS", 
            "safety_issue": "No", 
            "time_frame": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}